



INNOVATIVE DRUGS STIMULATING
LOCAL BLOOD PERFUSION

TO

ENABLE WOUND HEALING
TREAT MAJOR EYE DISEASES

AND MORE

Reto Naef, PhD, MBA
CEO and founder
Topadur Pharma AG


Reto.naef@topadur.com



Problem & solution

Chronic non-healing wounds, excessive scar formation
Ocular blood flow, medical cosmetics

Invention



Founded

2009 GmbH, 2015 AG
Headquarter: Schlieren CH
Employees: 17

FINANCIALS

13 Mio \$ equity
2.5 Mio \$ non diluting

NEXT EQUITY ROUND

12 Mio \$ mid 2019

expected exit: 2022

NEXT MILESTONES

FIH Q2-3/19

Leadership and board members with more than 150 years in Pharma R&D and marketing

Management

Leadership team



Dr. Guido Koch
COO & Development



Dr. Reto Naef
CEO & President



Dr. Hermann Tenor
Head research



Christina Attaalla
Finance, HR, Legal



Dr. Christian Ludin
Head development
Secretary o. B.

Board members



Prof. Dr. Günther Wess
R&D, diabetes



Dr. Dominik Escher
Serial founder, deal making



Pascal Brenneisen
HP, investor, legal, market

Wound healing
TOP-N53

1st priority



- **Diabetic foot ulcers**
- **Orphan ulcera**
- Decubitus
- Major surgery (incl. bone)
- Dental surgery

Ocular blood flow
TOP-N73a

2nd priority



- 1. **Glaucoma**
- 2. AMD
- 3. Diabetic Retinopathy

Scar prevention
TOP-N44

3rd priority



- **Burn wounds**
- Skin fibrosis
- Scleroderma
- Cosmetic surgery


Opportunistic R&D
TOP-N73b-d



- 1. ED - Topical
- 2. Pulmonary Arterial Hypertension
- 3. Medical Cosmetics
Alopecia, Skin aging

preclinical

clinical




Priority projects



TOP-N73a glaucoma

Opportunistic projects



Projects for early partnering

420 million	diabetic patients worldwide, double by 2026.
15-25%	lifetime risk of developing a diabetic foot ulcer
every 30 seconds	one lower limb amputation in diabetes patients occurred around the world
US\$13 billion	direct annual medical cost for the management of DFU in the United States

- Drug R&D platform, based on unique patented MoA
- TOP-N53: Unique potency and efficacy, new dual mode of action
- Strong IP
- Full pipeline with own and out-licensing development products
- Experienced leadership team and board
- Enormous market potential
- Promising ophthalmic program



TOP-N53
DIABETES FOOT

TOP-N44
BURN WOUNDS

TOP-N73a
GLAUCOMA

TOP-N73b-d
OPPORTUNISTIC R&D

HEALTH IS THE MOST IMPORTANT THING

AWARDS

- Winners Pitching Battle CEO day 2015
- Finalist Swiss Innovation Challenge 2015
- Winner Venture Leaders Life Science 2016
- Top 100 Swiss Startups 2016
- CTI label company 2016
- Winner IMD Startup 2016
- Top 100 Swiss Startups 2017
- Winner Swiss Innovation Challenge 2017
- Winner Venture Leaders China 2018
- Winner SEF high-tech Award 2018
- Top 100 Swiss Startups 2018

